The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.